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Summary:
Data were analyzed on 178 consecutive patients (median age 43 years) who underwent autologous blood stem cell transplantation (ABSCT) at a single institution to determine if CD34
+ subsets (CD34 + 38 − , CD34 + 33 − , CD34 + 33 + , CD34 + 41 + ) or various clinical factors affect hematopoietic engraftment independent of the total CD34
+ cell dose/kg. Using Cox proportional hazards models, the factors independently associated with rapid neutrophil engraftment were higher CD34
+ dose/kg, use of G-CSF post-ABSCT, and conditioning regimen (single-agent melphalan ± TBI slower). Factors independently associated with rapid platelet engraftment were higher CD34 + cell dose/kg, higher ratio of CD34 + 33 − /total CD34 
41

+ cells to a greater extent than total CD34
+ cells which may explain our observation that it resulted in slower platelet engraftment. In conclusion, the total CD34 + dose/kg was a better predictor of hematopoietic engraftment following ABSCT than the dose of any CD34 + subset. Platelet engraftment, however, was also influenced by the ratio of CD34 + 33 − /total CD34 + cells for unmanipulated autografts, and possibly by the CD34 + 41 + dose for autografts manipulated by CD34 + selection. The use of CD34 + subsets requires further investigation in predicting engraftment of autografts which undergo ex vivo manipulation. Keywords: hematopoietic stem cell transplantation; hematopoietic stem cells A prerequisite for safely treating patients with high-dose chemotherapy and autologous blood stem cell transplantation (ABSCT) is the ability to accurately predict the reconstitutive capacity of the autograft such that rapid and sustained hematopoietic recovery can be assured. At present, the marker most commonly utilized for this purpose is the total CD34 + cell dose. [1] [2] [3] Within the CD34 + cell
Correspondence: DA Stewart, Tom Baker Cancer Centre, 1331-29th Street NW, Calgary, Alberta, Canada, T2N 4N2 Received 5 October 1998; accepted 23 January 1999 population, however, exist both multipotent as well as committed, lineage-restricted progenitor cells. 4 Further characterization of the CD34 + cell population by flow cytometry can identify multipotent progenitor cells more accurately by the expression of CD45Ro, 5 and by the lack of expression of CD38, 6 CD33, 7 CD13, 8 and HLA-DR. 8, 9 Committed progenitor cells express CD34 along with antigens associated either with myeloid (CD33, CD13), 10 erythroid (CD71), 11 lymphoid (CD7, CD19), 12 or megakaryocytic lineage (CD41, CD61). 13, 14 The role of these various CD34
+ subsets in predicting the reconstitutive capacity of an autologous blood stem cell graft, however, is not well defined.
The main objective of this retrospective study was to determine if various CD34 + subsets, or various clinical factors are associated with engraftment of autologous blood stem cells independent of the total CD34 + cell dose. If so, the ability to predict the reconstitutive capacity of autologous blood stem cell grafts could be further refined. The particular CD34
+ subsets evaluated included the CD34 + 38 − and CD34 + 33 − subsets which contain multipotent progenitors, and the CD34 +
33
+ and CD34 + 41 + subsets which contain progenitors committed to neutrophil and platelet lineages, respectively.
Patients and methods
Patients
Between January 1993 and May 1998, 179 consecutive patients underwent ABSCT in Calgary. One of these patients was not evaluable for engraftment because she died less than 7 days post-ASCT. This patient was excluded from analysis. Table 1 lists characteristics of the remaining 178 patients who underwent ABSCT for the following disease indications: breast cancer (n = 66), lymphoma (n = 61), Hodgkin's disease (n = 17), myeloma (n = 9), germ cell tumor (n = 6), AML (n = 5), and other (n = 14). All patients provided written informed consent for ABSCT and all studies were approved by the institutional review board.
Blood stem cell collection
Patients were grouped according to their initial method of autologous blood stem cell mobilization. Group 1 patients 21 . Blood stem cell apheresis and cryopreservation methods have been previously described. 15 Autografts for 10 patients were processed with the CellPro CEPRATE SC system (CellPro, Bothell, WA, USA) prior to cryopreservation. Table 2 lists the high-dose chemotherapy regimens received by these patients. They varied according to disease and study protocol, and changed over time. Seventy-five percent of patients received either melphalan alone, melphalan plus TBI, or mitoxantrone, vinblastine, and cyclophosphamide (MVC). Table 3 illustrates the relationship between the high-dose regimen and the diagnosis. Autologous blood stem cells were infused on day 0. Daily G-CSF 300 (Ͻ70 kg) or 480 (Ͼ70 kg) g/day s.c. from day +7 until ANC Ͼ1.5 was used for consecutive patients starting in 1995. No G-CSF was used post-ABSCT for the 32 patients treated in 1993 and 1994. AML = acute myeloid leukemia; BrCa = breast cancer; CI = continuous infusion; DSRCT = desmoplastic small round cell tumor; EWS = Ewing's sarcoma; GCT = germ cell tumor; HD = Hodgkin's disease; MB = medulloblastoma; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma; Oligo = oligodendroglioma; OvCa = ovary cancer; TBI = total body irradiation.
Autologous stem cell transplantation
Table 3
Relationship between high-dose regimen and diagnosis Melphalan = melphalan ± TBI; MVC = mitoxantrone, vinblastine, cyclophosphamide.
Blood stem cell enumeration
Flow cytometric analysis was performed on an EPICS-XL (Beckman-Coulter, Hialeah, FL, USA) using a modified protocol. 16 + 41 + subsets were measured for 118 consecutive patients starting in 1996. Due to the high leukocyte counts of apheresis products, approximately 10 l of sample was used for staining (approximately 1 × 10 6 cells per test). Purified goat immunoglobulin (Caltag, Burlingame, CA, USA) was added to each tube prior to the addition of monoclonal antibodies to prevent nonantigen mediated binding via Fc receptors. After a 10-min incubation period, FITC, PE, or PC5-conjugated monoclonal antibodies -CD41, CD33, CD38, HLA-Dr, CD34, CD45, and isotype controls (Beckman-Coulter) were added according to the manufacturer's guidelines, and incubated a further 15 min at room temperature, in the dark. Subsequently, samples were lysed with 2 ml of pre-warmed (37°C) ammonium lysis buffer for 2 min, washed with 2 ml of PBS-0.1% sodium azide, and centrifuged for 5 min at 250 g. Cell pel-lets were resuspended in 0.5 ml PBS-0.1% sodium azide and analyzed immediately.
Before analyzing samples, the instruments were verified for system performance (optical alignment, fluorescence intensity, and color compensation) to ensure continuity of day to day results. A plot displaying log side scatter (LSSC) vs CD34 was used as the first of two gating histograms in order to identify SSClow and CD34
+ events. The SSClow CD34
+ events were then displayed in a second plot: forward scatter (FS) vs LSSC. The discrete cluster of CD34 + stem cells was gated, excluding any spurious signal from debris, granulocytes, platelets, and unlysed red blood cells. The gated CD34
+ cells were then displayed in a two parameter fluorescent histogram displaying the fluorescent signals from the monoclonal antibodies of interest used to subset CD34 + cells. Cursors were set using isotype controls as guidelines in establishing the levels of background fluorescence. Normal lymphocytes and monocytes in the apheresis products were also used as either positive and/or negative internal controls for antibodies such as CD33, CD38, and HLA-DR where expected antigen expression/absence has been previously characterized. A minimum of 2500 CD34 + cells were analyzed.
Statistics
Platelet engraftment was defined as the first of 3 consecutive days that the platelet count was у20 × 10 9 /l and increasing without platelet transfusions. Neutrophil engraftment was defined as the first of 3 consecutive days that the sum of segmented neutrophil plus band count was у0.5 × 10 9 /l and increasing. In univariate analysis, Spearman's rank correlation test was used for continuous independent variables. Kruskal-Wallis rank sum test was used for categorical independent variables. Cox proportional hazards models were then built to study the effect of a predictor with other variables being simultaneously controlled. Due to the nature of the data which was not normally distributed, logarithmic transformation was made to CD34 + cell dose/kg. To determine whether various CD34 + subsets were independently associated with engraftment, modeling was done using the proportion of the total CD34 + cell dose which was positive for the subset being analyzed (eg CD34 + 41 + total CD34 + ) rather than the absolute CD34 + subset/kg dose. This was done to avoid co-linearity because the total CD34 + subset/kg values were highly correlated with the total CD34 + cell/kg dose, whereas the proportions were not.
Cox proportional hazards models were used to determine if the following factors were independently associated with neutrophil or platelet engraftment: age, gender, number of prior chemotherapy regimens, prior radiotherapy, morphological evidence of bone marrow infiltration, stem cell mobilization regimen, autograft processing by positive CD34 + cell selection (CellPro CEPRATE SC system), conditioning regimen, use of TBI, use of G-CSF post-ABSCT, total CD34 + dose/kg, and proportional dose of various CD34 (Table 3) , it was felt inappropriate to analyze the effect of both of these two factors on engraftment. The high-dose regimen was chosen for analysis since it theoretically had a more direct effect on engraftment kinetics than diagnosis.
Results
Hematopoietic engraftment after ABSCT
The CD34
+ dose infused at the time of ABSCT ranged from 1.4 to 127.0 × 10 6 /kg (median = 6.4) for the 178 patients. The median time to neutrophil recovery у0.5 × 10 9 /l was 11 days (range 8-28), and to platelet recovery у20 × 10 9 /l was 12 days (range 7-1000+) post-ABSCT. Figure 1 illustrates the impact of CD34 + cell dose on engraftment. The proportion of patients who achieved neutrophil and platelet engraftment by day 11 (the median day of neutrophil engraftment for the 178 patients) was: 35% and 8% respectively with 1-3 × 10 6 CD34 + cells/kg; 33% and 21% respectively with 3-5 × 10 6 CD34 + cells/kg; 64% and 43% respectively with 5-10 × 10 6 CD34 + cells/kg; and 85% and 78% respectively with Ͼ10 × 10 6 CD34 + cells/kg. Figure 2 plots platelet engraftment by the CD34
+ cell dose for all 178 patients and demonstrates the fact that a definite plateau is not reached until the CD34 + dose approaches 15-20 × 10 6 /kg. All patients achieved neutrophil engraftment, but three patients did not achieve platelet engraftment. These three patients had CD34
+ cell doses of 1.4, 1.9 and 3.6 × 10 6 /kg. Five additional patients never achieved a platelet count Ͼ100. These five patients had CD34 + cell doses of 2.6, 3.0, 4.0, 5.2 and 7.1 × 10 6 /kg. Two of the five received autografts manipulated by positive CD34 + cell selection (CellPro CEPRATE SC system). Interestingly, seven out of these eight patients relapsed within a few months of ABSCT and died of recurrent cancer between 39 and 381 days post-ABSCT. Thus, uncontrolled cancer may have affected engraftment in these patients.
Correlation between CD34
+ subsets and hematopoietic engraftment after ABSCT For each subset, the percentage of the total CD34 + dose/kg infused is shown in the box plots of Figure 3 . Since the percentage of CD34 + 33 + cells is the reciprocal of CD34 + 33 − cells, it is not shown. Of note, the relative proportion of CD34 + subsets did not differ by the method of blood stem cell mobilization. Spearman-rank correlation assays were applied to assess the relationship between the total number of CD34 + cells/kg or the total number of a CD34 + subset/kg + subsets correlated with engraftment, the coefficients were higher for the total CD34 + cell dose/kg than for any particular CD34 + subset within the same cohort of patients. Tables 6 and 7 show the factors which were independently associated with hematopoietic engraftment by multivariate /kg (median 5.3 × 10 6 /kg). Platelet engraftment for these 10 patients occurred at a median of day 14.5 (11-38) compared with a median of 12 days (7-1000+) for the remaining 168 patients. The proportion of CD34 + 41 + cells/kg/total CD34 + cells/kg was Ͻ0.02 for all studied patients who received CD34
Multivariate analysis of factors potentially associated with hematopoietic engraftment
+ selected autografts, compared with only eight out of 116 patients (7%) whose autografts were not processed by CD34
+ selection (P Ͻ 0.00001). Further, the infused CD34 + 41 + cell dose/kg for the patients receiving CD34
+ selected autografts ranged from 0.04-0.23 × (median = 0.58 × 10 6 /kg) for the 116 patients who received unmanipulated autografts (P = 0.002). We found no evidence to indicate that the proportion or total dose of CD34 + 33 − cells was responsible for the slower platelet engraftment associated with the CEPRATE CD34 + selection process.
In absolute terms, the factor with the greatest impact on neutrophil recovery was the use of G-CSF post-ABSCT: median 15 days without G-CSF (range 11-28) vs 11 days with G-CSF (range 8-18) . The use of G-CSF post-ABSCT accounted for 20% of the variance in neutrophil engraftment. The effect of the high-dose regimen was more modest, accounting for 4% of the variance in neutrophil and in platelet engraftment. Engraftment occurred 1-2 days slower after melphalan than MVC or other regimens despite a median CD34
+ cell dose of 8.5 × 10 6 /kg for melphalan (1.7-127.0) vs 7.4 × 10 6 /kg for MVC (2.5-27.5) and 4.5 × 10 6 /kg for others (1.4-23.4) . TBI was used more commonly with melphalan than with other regimens but by multivariate analysis, TBI did not predict engraftment independent of the conditioning regimen. The effect of the conditioning regimen on neutrophil engraftment persisted when the multivariate analysis was performed within disease subgroups.
Discussion
In this study, factors independently associated with rapid neutrophil engraftment were higher CD34 + dose/kg, G-CSF post-ABSCT, and conditioning regimen (melphalan ± TBI slower than others). Factors independently associated with rapid platelet engraftment were higher CD34 + cell dose/kg, higher ratio of CD34 + 33 − /total CD34 + cells infused, conditioning regimen (MVC faster than other regimens), and no CD34
+ cell selection of the autograft. The total CD34 + cell dose/kg was the most important factor (accounting for 37% of the variance) for platelet engraftment and was second only to the use of G-CSF post-ABSCT for neutrophil engraftment (CD34 + dose and G-CSF accounting for 10% and 20% of the variance, respectively). Correlation between CD34
+ cell dose and engraftment has been well documented previously. 1, 18, 19 All CD34 + subsets studied correlated less well with hematopoietic recovery than did the total CD34 + cell dose/kg. There was a small impact of the CD34 + 33 − subset on platelet engraftment, but no detectable effect of any CD34 + subset on neutrophil engraftment. Possibly this was due to the use of G-CSF post-ABSCT for the majority of patients studied. The effect of post-ABSCT G-CSF on neutrophil recovery was so powerful that it may have masked a small effect of CD34 + subsets. The few patients whose autografts were processed by positive selection using the CellPro CEPRATE SC system experienced a median 2.5 day delay in platelet engraftment. This result is similar to that found in the only randomized controlled trial evaluating the CEPRATE device. 20 In our patients, the CellPro CEPRATE SC system seemed to deplete CD34
+ 41 + cells to a greater relative degree than total CD34 + cells. Although this finding is based on a relatively small number of patients, it suggests that the CD34 + 41 + subset may be more useful if the autograft is manipulated in some manner than if it is not manipulated. The possible importance of CD34 + subsets should be studied further in autografts processed by chemotherapy purging, positive or negative selection, or ex vivo expansion.
The results of this study differ from some studies which reported a stronger association between the CD34 + subsets and engraftment. [21] [22] [23] [24] One possible reason for this difference is the fact that Ͼ85% of patients in this study had stem cells collected by a single apheresis procedure whereas other studies generally utilized multiple days of apheresis. There is some evidence from these studies that the relative proportion of CD34 + subsets varies with successive days of apheresis. It is therefore possible that subsets may be more important when autografts are collected over multiple days than when collected by a single procedure.
Secondly, previous reports did not utilize similar statistical methods. Perhaps most importantly in this regard, we found that logarithmic transformation of the CD34 + cell dose/kg significantly improved its correlation with engraftment. Previous reports did not perform logarithmic transformation of the CD34 + cell dose/kg, and therefore, were more likely to find a significant impact of other factors on engraftment, including CD34 + subsets. Several other differences exist in statistical methods. In univariate analysis, Derksen and colleagues 21 did not compare the association between engraftment and total CD34
+ cell dose with that of the CD34 + subset dose within the same cohort of patients, as illustrated in Tables 4 and 5 . Further, they reported that CD34
+ 33 − cells and CD34 + 41 + cells correlated significantly better with neutrophil and platelet engraftment than did total CD34 + cells. However, their analysis attached statistical significance to a P value of Ͻ0.05 despite performing multiple comparisons, and must be viewed with some degree of caution. Caution should also be exercised in interpreting studies utilizing arbitrary cutoffs for CD34 + and CD34
+ subset doses rather than using pre-specified cutoffs, or analyzing the data as continuous variables. 22 Results of statistical significance can change drastically depending upon where the arbitrary cutoff is made. For example, Figure 4 was based on a CD34
+ 33 − /CD34 + ratio of 0.30 which was the median ratio of all patients in the study. If a similar plot was made using a cutoff of 0.50, the engraftment curves for CD34 + doses Ͻ5 × 10 6 /kg would no longer significantly differ. Similar to our study, Pecora and colleagues 24 found that the total CD34 + cell dose correlated better with engraftment than did the CD34 + 33 − proportion of the total CD34 + dose. Using multivariate analysis, however, they found a stronger association than we did between hematopoietic engraftment and both the proportion of CD34
+ 33 − /CD34 + infused and the absolute CD34 + 33 − dose/kg. This may be due to the fact that they had a larger sample size and did not perform logarithmic transformation of the total CD34 + dose/kg in their analysis. Finally, weaknesses of our study and prior studies include a retrospective approach, heterogeneous patient populations, use of various high-dose and mobilization regimens, variable use of G-CSF post-ABSCT, missing CD34 + subset data for some subjects, and small sample sizes. These plus other factors such as differences in methods of CD34
+ subset enumeration and different apheresis techniques may be responsible for the different results found in our study relative to previous reports. The finding that single-agent high-dose melphalan given entirely on day −1 is associated with slower hematopoietic engraftment than other high-dose regimens has not been previously reported. It is known that melphalan has a short half-life of elimination, and therefore, it is unlikely that persistence of active drug at the time of stem cell infusion is the cause for delayed engraftment. 25 Possibly, melphalan damages the marrow microenvironment to a greater extent than other regimens although this has not been proven. The MVC regimen resulted in more rapid engraftment than other regimens. This is likely a non-myeloablative regimen, and therefore, is possibly less damaging to bone marrow stroma as well.
In conclusion, the total CD34 + dose/kg was a better predictor of hematopoietic engraftment following ABSCT than the dose of any CD34
+ subset. The CD34 + subsets which added a small amount of information regarding platelet engraftment were CD34
+ 33 − cells in cases of unmanipulated autografts containing Ͻ5 × 10 6 CD34 + cells/kg, and CD34
+
41
+ cells in the setting of CellPro CEPRATE SC system CD34 + selection.
